866-997-4948(US-Canada Toll Free)

Chronic Lower Back Pain (CLBP)-Market Insights, Epidemiology and Market Forecast-2028

Published By :

DelveInsight

Published Date : Jul 2019

Category :

Pharmaceutical

No. of Pages : 301 Pages

DelveInsights Chronic Lower Back Pain (CLBP)- Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of CLBP in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of CLBP from 2017 to 2028 segmented by the seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.
Geography Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2017-2028
Chronic Lower Back Pain (CLBP) Disease Understanding and Treatment Algorithm
Chronic low back pain (CLBP) is defined as pain that persists for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain has been treated. Low back pain is very common and at one point everyone may have faced this problem. The exact cause of lower back pain is unknown. Lower back pain that is long-term (for more than 3 months) is called chronic low back pain, this condition might originate from an injury, disease, or stress on different structures of the body, and pain may vary significantly and may be felt as bone pain, nerve pain, or muscle pain.
When assessing CLBP, clinicians should inquire about pain onset, severity, chronicity, and other factors such as painful experience. Pain severity may form a bi-dimensional or a one-dimensional scale depending on the specific instruments tested. High inter-correlations between pain-intensity measures and pain-related disability measures support the concept of using them as a unitary construct of pain severity. Various scales are used by experts in order to assess the severity of pain in CLBP patients, two of the most widely used are Visual Analogue Scale (VAS) and Verbal Rating Scale (VRS).
The DelveInsights CLBP market report gives a thorough understanding of the CLBP by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for CLBP in the US, Europe, and Japan.
Chronic Lower Back Pain (CLBP) Epidemiology
The CLBP epidemiology division provides insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsights report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalent Population, Gender-Specific Prevalent Population, Age-Specific Prevalent Population, Severity-Specific Prevalent Population, Number of CLBP Patients on Prescription Medications by different Class and Number of CLBP Patients on Opioids by low dose, high dose, and overdose] scenario of CLBP in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2028.
As per DelveInsights analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries, except Japan, wherein males occupy a larger patient pool than females. According to DelveInsights estimations, the total prevalent population of CLBP in the 7MM was observed to be 73,802,461 in 2017, which is expected to increase during the study period i.e. 2017-2028. Furthermore, the total diagnosed prevalent population of CLBP in the 7MM was assessed to be 44,281,476 in 2017.
The estimates show the highest diagnosed prevalence of CLBP in the United States with more than 20 million cases in 2017. Among the European 5 countries, the United Kingdom had the highest diagnosed prevalent population of CLBP, followed by Germany and France. On the other hand, Spain had the lowest diagnosed prevalent population. Additionally, Japan was observed with 8,865,879 diagnosed prevalent cases for CLBP in 2017. According to DelveInsights analysis, it has been observed that CLBP is mostly diagnosed in the age group of 40-69. Moreover, we have observed that moderate to severe are the majorly diagnosed CLBP patients.
Chronic Lower Back Pain (CLBP) Drug Chapters
This segment of the CLBP report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
NKTR-181 (Nektar Therapeutics), a long-lasting opioids analgesic, acts as a selective mu-opioid receptor (MOR) agonist, is aimed to provide potent drug relief without the inherently high levels of euphoria. Phase III trial has been completed and another phase III trial currently under evaluation. NKTR-181 has been granted Fast Track designation by the US FDA and new drug application (NDA) has been filed for this drug by the company. NKTR-181 is the first analgesic opioid molecule to exhibit a reduction in specific CNS-mediated side effects, like euphoria, through the strategic alteration of brain-entry kinetics.
Buprenorphine (CAM2038: Braeburn Pharmaceuticals/Camurus) acts as a partial agonist at the mu opioid receptor and also exhibits antagonistic effects at the kappa opioid receptor. This drug is being evaluated in Phase III clinical trials Opioid Use Disorder; Chronic Pain, and Chronic Lower Back Pain. The company is expecting long-term efficacy and results of pivotal Phase III studies by the first half of 2019. The drug has an advantage in the administration as it is weekly/monthly SC depot, which avoids the healthcare professional requirement. If approved, CAM2038 offers an HCP-administered dosing regimen that will allow patients to transition from daily oral opioids to manage chronic pain, while potentially minimizing the risks of abuse, misuse, and diversion.
Egalet-002 (Egalet Corporation), is pure opioid which acts as opioid mu and kappa agonist; opioid delta agonists. The US FDA has granted Fast Track Designation for this drug. Eaglet Corporation has filed the NDA for this drug candidate. Egalet Corporation initially anticipated the NDA submission of Egalet-002 in 2019. Although the company completed phase III studies for Egalet-002 with proven efficacy, it has determined to delay indefinitely the previously-announced anticipated 2019 filing date for the Egalet-002 NDA, unless the availability of a partner to share the cost. The company is actively seeking partners for Egalet-002 as well as other product candidates.
Tanezumab (Pfizer/Eli Lilly and Company) is the first-in-class, non-opioids treatment which acts by selectively targeting, binding to and inhibiting nerve growth factor (NGF). The drug is being evaluated in Phase III clinical trials for CLBP. The US FDA has granted Fast Track designation for Tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and CLBP. But a lower dose of the drug, tanezumab, failed to alleviate pain when compared with a placebo, the companies said in a statement.
Rexlemestrocel-L (MPC-06-ID; Mesoblast) is an allogeneic mesenchymal precursor cell (MPC) product candidate and Phase III trials are being conducted for this potent drug candidate. This drug works as Cell Replacement: Proteoglycan & collagen stimulant.
Chronic Lower Back Pain (CLBP) Market Outlook
The CLBP market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criterias, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
A number of medications have proven to be effective in chronic pain disorders and their use individually or in combination should improve the management of chronic pain. Especially for neuropathic pain, the medications recommended as first-line treatments include TCAs, SNRIs, calcium channel 2- ligands, and lidocaine patch. Opioid analgesics and tramadol are recommended as second-line treatments that can be considered for first-line use in selected clinical circumstances.
A thorough understanding of pain mechanisms and good communication between physicians and patients are required to improve patient outcomes. Avoiding ineffective treatments and maximizing the treatments that have been proven beneficial in clinical trials (i.e., evidence-based treatments) are likely to produce better outcomes than have often been experienced by clinicians and patients in the management of chronic pain. Additionally, identifying and co-managing pain that is comorbid with psychiatric disorders have promise for improving both the physical and psychological outcomes.
Furthermore, the multimodality treatment of chronic pain incorporates not only this approach to pharmacological treatment, but also non-pharmacological strategies such as interventional pain management, physiotherapy, psychotherapy, and pain rehabilitation.
The market size of CLBP in the 7MM is expected to grow at a CAGR of 4.84% for the study period (2017-2028). The current market size of CLBP is entirely dependent on supportive treatment regimens, along with the drugs that have been approved to treat comorbidities associated with CLBP, and those that are in general approved for chronic pain. The supportive therapies are either prescribed as monotherapy or are given in combination. The prescription of these therapies varies greatly among the 7MM countries, i.e. while opioids remain the mainstay of treatment in the United States, NSAIDs are more commonly prescribed in the EU-5 countries.
With the launch of the effective branded targeted therapies, the market is going to rise which will introduce another USD 623.19 million in 2022, to the overall therapies market. Of the emerging therapies, Braeburn Pharmaceuticals/Camurus, Pfizer/Eli Lilly and Company, Mesoblast, Nektar Therapeutics, Egalet Corporation are expected to enter the treatment market, with their respective products, during the forecast period [2019-2028]. The current opioid prescription market is expected to decline in the coming years. This may be attributed to the fact that in the coming years, patients with CLBP will switch from currently prescribed opioids to emerging opioid therapies, such as, NKTR-181 (Nektar Therapeutics), Buprenorphine (CAM2038; Braeburn Pharmaceuticals/Camurus), and Egalet-002 (Egalet Corporation), which have proven safety and efficacy in CLBP patients.
Chronic Lower Back Pain (CLBP) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of Chronic Lower Back Pain (CLBP) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world and expected the launch of emerging therapies during the forecast period of 2019-2028. Companies across the globe are thoroughly working toward the development of new treatment therapies for CLBP.
More than a dozen companies have shifted their focus towards this therapeutic area. To name a few: Braeburn Pharmaceuticals, Camurus, Regeneron Pharmaceuticals, Teva Pharmaceutical, Pfizer, Eli Lilly and Company, Mesoblast, Nektar Therapeutics, Egalet Corporation, Axsome Therapeutics, Allodynic Therapeutics, Astellas Pharma, Grnenthal GmbH, Frontier Biotechnologies, DiscGenics, Yuhan Corporation, Semnur Pharmaceuticals, Sollis Therapeutics, SpineThera, Stayble Therapeutics, AnGes MG, and others. While some of these are in the early stage of development, yet others have reached the NDA filling stage in the development process.
CLBP Report Insights
Patient Population
Therapeutic Approaches
Pipeline Analysis
Market Size and Trends
Market Opportunities
Impact of upcoming Therapies
CLBP Report Key Strengths
10 Years Forecast
7MM Coverage
Epidemiology Segmentation
Key Cross Competition
Market Size by Therapies
Drugs Uptake
CLBP Report Assessment
Pipeline Product Profiles
Key Products and Key Players
Market Drivers and Barriers
Key Benefits
This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the CLBP market
Organize sales and marketing efforts by identifying the best opportunities for CLBP market
To understand the future market competition in the CLBP market.
1. Key Insights
2. Chronic Lower Back Pain (CLBP) Market Overview at a Glance
2.1. Market (%) Distribution of CLBP in 2017
2.2. Market (%) Distribution of CLBP in 2028
3. Chronic Lower Back Pain (CLBP): Disease Background and Overview
3.1. Introduction
3.2. Signs and Symptoms
3.3. Causes and Risk Factors
3.4. Genetics of Chronic Lower Back Pain
3.5. Pathophysiology
3.5.1. Degenerative Cascade
3.5.2. Mechanistic factors involved behind the cause of CLBP
3.5.3. Neuroplasticity and central sensitization
3.5.4. Connective tissue remodeling in CLBP
3.5.5. Effect of connective tissue pathology on sensory afferent modulation
3.5.6. CLBP and Connective Tissue Remodeling
3.5.7. Pathophysiological model
3.6. Type of pain
3.6.1. Diskogenic pain
3.6.2. Lumbar spinal stenosis
3.6.3. Sacroiliac pain
3.6.4. Facet-joint pain
3.6.5. Radicular pain
3.6.6. Muscular pain
3.7. Diagnosis
3.7.1. Clinical History
3.7.2. Physical Examination
3.7.3. Imaging Guidelines
3.7.4. Assessment of Pain
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent Population of Chronic Lower Back Pain in the 7MM
4.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the 7MM
4.4. Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM
4.5. Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM
4.6. Severity-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM
5. United States Epidemiology
5.1. Assumptions and Rationale
5.2. Total Prevalent Population of Chronic Lower Back Pain in the United States
5.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United States
5.4. Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States
5.5. Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States
5.6. Severity-Specific Diagnosed Prevalence of CLBP in the United States
5.7. Number of CLBP Patients on Prescription Medications by different Class in the United States
5.8. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the United States
6. EU5 Epidemiology
6.1. Germany Epidemiology
6.1.1. Assumptions and Rationale
6.1.2. Total Prevalent Population of Chronic Lower Back Pain in Germany
6.1.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Germany
6.1.4. Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Germany
6.1.5. Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Germany
6.1.6. Severity-Specific Diagnosed Prevalence of CLBP in Germany
6.1.7. Number of CLBP Patients on Prescription Medications by different Class in Germany
6.1.8. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Germany
6.2. France Epidemiology
6.2.1. Assumptions and rationale
6.2.2. Total Prevalent Population of Chronic Lower Back Pain in France
6.2.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in France
6.2.4. Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in France
6.2.5. Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in France
6.2.6. Severity-Specific Diagnosed Prevalence of CLBP in France
6.2.7. Number of CLBP Patients on Prescription Medications by different Class in France
6.2.8. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in France
6.3. Italy Epidemiology
6.3.1. Assumptions and Rationale
6.3.2. Total Prevalent Population of Chronic Lower Back Pain in Italy
6.3.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Italy
6.3.4. Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Italy
6.3.5. Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Italy
6.3.6. Severity-Specific Diagnosed Prevalence of CLBP in Italy
6.3.7. Number of CLBP Patients on Prescription Medications by different Class in Italy
6.3.8. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Italy
6.4. Spain Epidemiology
6.4.1. Assumptions and Rationale
6.4.2. Total Prevalent Population of Chronic Lower Back Pain in Spain
6.4.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Spain
6.4.4. Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Spain
6.4.5. Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Spain
6.4.6. Severity-Specific Diagnosed Prevalence of CLBP in Spain
6.4.7. Number of CLBP Patients on Prescription Medications by different Class in Spain
6.4.8. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Spain
6.5. United Kingdom Epidemiology
6.5.1. Assumptions and Rationale
6.5.2. Total Prevalent Population of Chronic Lower Back Pain in the United Kingdom
6.5.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United Kingdom
6.5.4. Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United Kingdom
6.5.5. Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United Kingdom
6.5.6. Severity-Specific Diagnosed Prevalence of CLBP in the United Kingdom
6.5.7. Number of CLBP Patients on Prescription Medications by different Class in the United Kingdom
6.5.8. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the United Kingdom
7. Japan Epidemiology
7.1. Assumptions and Rationale
7.2. Total Prevalent Population of Chronic Lower Back Pain in Japan
7.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan
7.4. Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan
7.5. Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan
7.6. Severity-Specific Diagnosed Prevalence of CLBP in Japan
7.7. Number of CLBP Patients on Prescription Medications by different Class in the Japan
7.8. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the Japan
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Non-pharmacological treatments
8.2. Pharmacologic Treatments
8.2.1. Non-opioids Analgesics
8.2.2. Opioid Analgesics
8.2.3. Tramadol W
8.2.4. Antidepressants
8.2.5. Muscle relaxants
8.3. Treatment Algorithm
9. Proposed Guidelines for Chronic Lower Back Pain
9.1. NICE Guidelines
9.1.1. Recommendation
9.2. Center of disease control and prevention (CDC) Guidelines
9.2.1. Recommendations
9.3. American College of Physicians (ACP) Guidelines
9.3.1. Recommendations
10. Unmet Needs
11. Marketed Products
11.1. Cymbalta (Duloxetine): Eli Lilly and Company
11.1.1. Product Description
11.1.2. Regulatory Milestones
11.1.3. Clinical development
11.1.4. Safety and Efficacy
11.1.5. Advantages and disadvantages
11.1.6. Product Profile
11.2. Xtampza: Collegium Pharmaceutical
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Clinical Development
11.2.4. Safety and Efficacy
11.2.5. Product Profile
11.3. Butrans (buprenorphine): Purdue Pharma
11.3.1. Product Description
11.3.2. Regulatory Milestones
11.3.3. Clinical Development
11.3.4. Safety and Efficacy
11.3.5. Product Profile
11.4. Belbuca: BioDelivery Sciences International
11.4.1. Product Description
11.4.2. Regulatory Milestones
11.4.3. Clinical Development
11.4.4. Safety and Efficacy
11.4.5. Product Profile
12. Emerging Therapies
12.1. Key Cross Competition
12.2. NKTR-181: Nektar Therapeutics
12.2.1. Drug Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
12.3. Tanezumab: Eli Lilly/Pfizer
12.3.1. Product Description
12.3.2. Other Developmental Activities
12.3.3. Clinical Development
12.3.4. Safety and Efficacy
12.3.5. Product Profile
12.4. Fasinumab: Regeneron Pharmaceuticals/ Teva Pharmaceuticals
12.4.1. Product Description
12.4.2. Other Developmental Activities
12.4.3. Clinical Development
12.4.4. Safety and Efficacy
12.4.5. Product Profile
12.5. MPC-06-ID (Rexlemestrocel-L): Mesoblast
12.5.1. Drug Description
12.5.2. Other Developmental Activities
12.5.3. Clinical Development
12.5.4. Safety and Efficacy
12.5.5. Product Profile
12.6. CAM2038: Braeburn Pharmaceuticals/Camurus
12.6.1. Drug Description
12.6.2. Other Developmental Activities
12.6.3. Clinical Development
12.6.4. Safety and Efficacy
12.6.5. Product Profile
12.7. Egalet-002: Egalet Corporation
12.7.1. Drug Description
12.7.2. Other Developmental Activities
12.7.3. Clinical Development
12.7.4. Safety and Efficacy
12.7.5. Product Profile
12.8. ALLOD-2: Allodynic Therapeutics
12.8.1. Drug Description
12.8.2. Other Developmental Activities
12.8.3. Clinical Development
12.8.4. Product Profile
12.9. Clonidine Micropellets (STX-051): Sollis Therapeutics
12.9.1. Product Description
12.9.2. Product Development Activities
12.9.3. Clinical development
12.9.4. Product Profile
12.10. GRT6005: Grnenthal GmbH
12.10.1. Drug Description
12.10.2. Other Developmental Activities:
12.10.3. Clinical Development
12.10.4. Safety and Efficacy
12.10.5. Product profile
12.11. AB001: Frontier Biotechnologies
12.11.1. Drug Description
12.11.2. Other developmental activities
12.11.3. Clinical Development
12.11.4. Safety and efficacy
12.11.5. Product profile
12.12. ASP7962: Astellas Pharma Europe B.V.
12.12.1. Drug Description
12.12.2. Clinical Development
12.12.3. Safety and Efficacy
12.12.4. Product profile
12.13. AXS-02 (disodium zoledronate tetrahydrate): Axsome Therapeutics
12.13.1. Drug description
12.13.2. Other Developmental activities
12.13.3. Clinical Development
12.13.4. Product Profile
12.14. YH14618: Yuhan Corporation
12.14.1. Drug description
12.14.2. Other developmental activities
12.14.3. Clinical development
12.14.4. Product profile
12.15. IDCT: DiscGenics
12.15.1. Drug Description
12.15.2. Other Developmental Activities
12.15.3. Clinical Developmental Activities
12.15.4. Safety and efficacy
12.15.5. Product Profile
12.16. SP-102: Semnur Pharmaceuticals
12.16.1. Product Description
12.16.2. Other Developmental Activities
12.16.3. Clinical Development
12.16.4. Safety and Efficacy
12.16.5. Product Profile
12.17. SX600: SpineThera
12.17.1. Product Description
12.17.2. Other Developmental Activities
12.17.3. Clinical Development
12.17.4. Product Profile
13. Chronic Lower Back Pain (CLBP): 7MM Market Analysis
13.1. Key Findings
13.2. Market Size of Chronic Lower Back Pain in 7MM
13.3. Market Size of Chronic Lower Back Pain by Therapies in the 7MM
13.4. Opioid Epidemic across the 7MM Countries
14. United States: Market Outlook
14.1. United States Market Size
14.1.1. Total Market size of Chronic Lower Back Pain in the United States
14.1.2. Market Size of Chronic Lower Back Pain by Therapies in the US
15. EU-5 countries: Market Outlook
15.1. Germany Market Size
15.1.1. Total Market size of Chronic Lower Back Pain in Germany
15.1.2. Market Size of Chronic Lower Back Pain by therapies in Germany
15.2. France Market Size
15.2.1. Total Market size of Chronic Lower Back Pain in France
15.2.2. Market Size of Chronic Lower Back Pain by therapies in France
15.3. Italy Market Size
15.3.1. Total Market size of Chronic Lower Back Pain in Italy
15.3.2. Market Size of Chronic Lower Back Pain by therapies in Italy
15.4. Spain Market Size
15.4.1. Total Market size of Chronic Lower Back Pain in Spain
15.4.2. Market Size of Chronic Lower Back Pain by therapies in Spain
15.5. United Kingdom Market Size
15.5.1. Total Market size of Chronic Lower Back Pain in the United Kingdom
15.5.2. Market Size of Chronic Lower Back Pain by therapies in the UK
16. Japan Market Outlook
16.1. Japan Market Size
16.1.1. Total Market size of Chronic Lower Back Pain in Japan
16.1.2. Market Size of Chronic Lower Back Pain by therapies in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

List of Table

Table 1: Risk factors for occurrence and chronicity of low back pain
Table 2: Cause of Muscle connective tissue fibrosis
Table 3: Total Prevalent Population of Chronic Lower Back Pain in the 7MM (2017-2028)
Table 4: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the 7MM (2017-2028)
Table 5: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM (2017-2028)
Table 6: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM (2017-2028)
Table 7: Severity-Specific Diagnosed Prevalence of CLBP in the 7MM (2017-2028)
Table 8: Total Prevalent Population of Chronic Lower Back Pain in the US (2017-2028)
Table 9: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the US (2017-2028)
Table 10: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the US (2017-2028)
Table 11: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States (2017-2028)
Table 12: Severity-Specific Diagnosed Prevalence of CLBP in the US (2017-2028)
Table 13: Number of CLBP Patients on Prescription Medications by different Class in the US (2017-2028)
Table 14: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the US (2017-2028)
Table 15: Total Prevalent Population of Chronic Lower Back Pain in Germany (2017-2028)
Table 16: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Germany (2017-2028)
Table 17: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Germany (2017-2028)
Table 18: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Germany (2017-2028)
Table 19: Severity-Specific Diagnosed Prevalence of CLBP in Germany (2017-2028)
Table 20: Number of CLBP Patients on Prescription Medications by different Class in Germany (2017-2028)
Table 21: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Germany (2017-2028)
Table 22: Total Prevalent Population of Chronic Lower Back Pain in France (2017-2028)
Table 23: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in France (2017-2028)
Table 24: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in France (2017-2028)
Table 25: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in France (2017-2028)
Table 26: Severity-Specific Diagnosed Prevalence of syndromic CLBP in France (2017-2028)
Table 27: Number of CLBP Patients on Prescription Medications by different Class in France (2017-2028)
Table 28: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in France (2017-2028)
Table 29: Total Prevalent Population of Chronic Lower Back Pain in Italy (2017-2028)
Table 30: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Italy (2017-2028)
Table 31: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Italy (2017-2028)
Table 32: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Italy (2017-2028)
Table 33: Severity-Specific Diagnosed Prevalence of CLBP in Italy (2017-2028)
Table 34: Number of CLBP Patients on Prescription Medications by different Class in Italy (2017-2028)
Table 35: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Italy (2017-2028)
Table 36: Total Prevalent Population of Chronic Lower Back Pain in Spain (2017-2028)
Table 37: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Spain (2017-2028)
Table 38: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Spain (2017-2028)
Table 39: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Spain (2017-2028)
Table 40: Severity-Specific Diagnosed Prevalence of CLBP in Spain (2017-2028)
Table 41: Number of CLBP Patients on Prescription Medications by different Class in Spain (2017-2028)
Table 42: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Spain (2017-2028)
Table 43: Total Prevalent Population of Chronic Lower Back Pain in the United Kingdom (2017-2028)
Table 44: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United Kingdom (2017-2028)
Table 45: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United Kingdom (2017-2028)
Table 46: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United Kingdom (2017-2028)
Table 47: Severity-Specific Diagnosed Prevalence of CLBP in the UK (2017-2028)
Table 48: Number of CLBP Patients on Prescription Medications by different Class in the UK (2017-2028)
Table 49: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the UK (2017-2028)
Table 50: Total Prevalent Population of Chronic Lower Back Pain in Japan (2017-2028)
Table 51: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan (2017-2028)
Table 52: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2017-2028)
Table 53: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2017-2028)
Table 54: Severity-Specific Diagnosed Prevalence of CLBP in Japan (2017-2028)
Table 55: Number of CLBP Patients on Prescription Medications by different Class in Japan (2017-2028)
Table 56: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Japan (2017-2028)
Table 57: Summary of the efficacy of physical treatments for chronic LBP
Table 58: The American College of Physicians Guideline Grading System
Table 59: Cymbalta, Clinical Trial Description, 2019
Table 60: Xtampza ER, Clinical Trial Description, 2019
Table 61: Buprenorphine, Clinical Trial Description, 2019
Table 62: Belbuca, Clinical Trial Description, 2019
Table 63: Key Cross Competition: Emerging Therapies
Table 64: Key Cross Competition: Emerging Therapies (Continued)
Table 65: Key Cross Competition: Emerging Therapies (Continued)
Table 66: Key Cross Competition: Emerging Therapies (Continued)
Table 67: NKTR-181, Clinical Trial Description, 2019
Table 68: Tanezumab, Clinical Trial Description 2019
Table 69: Fasinumab, Clinical Trial Description, 2019
Table 70: Rexlemestrocel-L, Clinical Trial Description, 2019
Table 71: CAM2038, Clinical Trial Description, 2019
Table 72: Egalet-002, Clinical Trial Description, 2019
Table 73: ALLOD-2, Clinical Trial Description, 2019
Table 74: Clonidine Micropellets, Clinical Trial Description, 2019
Table 75: GRT6005, Clinical Trial Description, 2019
Table 76: AB001, Clinical Trial Description, 2019
Table 77: ASP7962, Clinical Trial Description, 2019
Table 78: AXS-02, Clinical Trial Description, 2019
Table 79: YH14618, Clinical Trial Description, 2019
Table 80: IDCT, Clinical Trial Description, 2019
Table 81: SP-102, Clinical Trial Description, 2019
Table 82: SX600, Clinical Trial Description, 2019
Table 83: Market Size of Chronic Lower Back Pain in 7MM in USD Million (2017-2028)
Table 84: Market Size of Chronic Lower Back Pain by therapies in the 7MM, in USD Million (2017-2028)
Table 85: Expected Launch Date of Emerging Drugs in the United States
Table 86: The US Market Size of Chronic Lower Back Pain in USD Million (2017-2028)
Table 87: Market Size of Chronic Lower Back Pain by therapies in the United States, in USD Million (2017-2028)
Table 88: Expected Launch Date of Emerging Drugs in Europe
Table 89: Germany Market Size of Chronic Lower Back Pain in USD Million (2017-2028)
Table 90: Market Size of Chronic Lower Back Pain by therapies in Germany, in USD Million (2017-2028)
Table 91: France Market Size of Chronic Lower Back Pain in USD Million (2017-2028)
Table 92: Market Size of Chronic Lower Back Pain by therapies in France, in USD Million (2017-2028)
Table 93: Italy Market Size of Chronic Lower Back Pain in USD Million (2017-2028)
Table 94: Market Size of Chronic Lower Back Pain by therapies in Italy, in USD Million (2017-2028)
Table 95: Spain Market Size of Chronic Lower Back Pain in USD Million (2017-2028)
Table 96: Market Size of Chronic Lower Back Pain by therapies in Spain, in USD Million (2017-2028)
Table 97: The UK Market Size of Chronic Lower Back Pain in USD Million (2017-2028)
Table 98: Market Size of Chronic Lower Back Pain by therapies in the United Kingdom, in USD Million (2017-2028)
Table 99: Expected Launch Date of Emerging Drugs in Japan
Table 100: Japan Market Size of Chronic Lower Back Pain in USD Million (2017-2028)
Table 101: Market Size of Chronic Lower Back Pain by therapies in Japan, in USD Million (2017-2028)

List of Chart

Figure 1: Types of Lower Back Pain
Figure 2: Signs and Symptoms of CLBP
Figure 3: Pathophysiological model for chronic low back pain linking somatic and behavioral components
Figure 4: Relationship describing therapeutic inventions and pathogenic mechanism
Figure 5: Types of Pain involved in CLBP mechanism
Figure 6: Definitions of Chronic Lower Back Pain
Figure 7: Total Prevalent Population of Chronic Lower Back Pain in the 7MM (2017-2028)
Figure 8: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the 7MM (2017-2028)
Figure 9: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM (2017-2028)
Figure 10: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM (2017-2028)
Figure 11: Severity-Specific Diagnosed Prevalence of CLBP in the 7MM (2017-2028)
Figure 12: Total Prevalent Population of Chronic Lower Back Pain in the US (2017-2028)
Figure 13: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the US (2017-2028)
Figure 14: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the US (2017-2028)
Figure 15: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States (2017-2028)
Figure 16: Severity-Specific Diagnosed Prevalence of CLBP in the US (2017-2028)
Figure 17: Number of CLBP Patients on Prescription Medications by different Class in the US (2017-2028)
Figure 18: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the US (2017-2028)
Figure 19: Total Prevalent Population of Chronic Lower Back Pain in Germany (2017-2028)
Figure 20: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Germany (2017-2028)
Figure 21: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Germany (2017-2028)
Figure 22: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Germany (2017-2028)
Figure 23: Severity-Specific Diagnosed Prevalence of CLBP in Germany (2017-2028)
Figure 24: Number of CLBP Patients on Prescription Medications by different Class in Germany (2017-2028)
Figure 25: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Germany (2017-2028)
Figure 26: Total Prevalent Population of Chronic Lower Back Pain in France (2017-2028)
Figure 27: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in France (2017-2028)
Figure 28: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in France (2017-2028)
Figure 29: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in France (2017-2028)
Figure 30: Severity-Specific Diagnosed Prevalence of CLBP in France (2017-2028)
Figure 31: Number of CLBP Patients on Prescription Medications by different Class in France (2017-2028)
Figure 32: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in France (2017-2028)
Figure 33: Total Prevalent Population of Chronic Lower Back Pain in Italy (2017-2028)
Figure 34: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Italy (2017-2028)
Figure 35: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Italy (2017-2028)
Figure 36: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Italy (2017-2028)
Figure 37: Severity-Specific Diagnosed Prevalence of CLBP in Italy (2017-2028)
Figure 38: Number of CLBP Patients on Prescription Medications by different Class in Italy (2017-2028)
Figure 39: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Italy (2017-2028)
Figure 40: Total Prevalent Population of Chronic Lower Back Pain in Spain (2017-2028)
Figure 41: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Spain (2017-2028)
Figure 42: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Spain (2017-2028)
Figure 43: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Spain (2017-2028)
Figure 44: Severity-Specific Diagnosed Prevalence of CLBP in Spain (2017-2028)
Figure 45: Number of CLBP Patients on Prescription Medications by different Class in Spain (2017-2028)
Figure 46: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Spain (2017-2028)
Figure 47: Total Prevalent Population of Chronic Lower Back Pain in the United Kingdom (2017-2028)
Figure 48: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United Kingdom (2017-2028)
Figure 49: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United Kingdom (2017-2028)
Figure 50: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United Kingdom (2017-2028)
Figure 51: Severity-Specific Diagnosed Prevalence of CLBP in the UK (2017-2028)
Figure 52: Number of CLBP Patients on Prescription Medications by different Class in the UK (2017-2028)
Figure 53: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the UK (2017-2028)
Figure 54: Total Prevalent Population of Chronic Lower Back Pain in Japan (2017-2028)
Figure 55: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan (2017-2028)
Figure 56: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2017-2028)
Figure 57: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain CLBP in Japan (2017-2028)
Figure 58: Severity-Specific Diagnosed Prevalence of CLBP in Japan (2017-2028)
Figure 59: Number of CLBP Patients on Prescription Medications by different Class in Japan (2017-2028)
Figure 60: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Japan (2017-2028)
Figure 61: The Vicious Circle showing the interaction of influencing factors
Figure 62: Treatment Algorithm for Chronic Low Back Pain
Figure 63: Unmet needs
Figure 64: Market Size of Chronic Lower Back Pain in the 7MM in USD Million (2017-2028)
Figure 65: Market Size of Chronic Lower Back Pain by therapies in the 7MM, in USD Million (2017-2028)
Figure 66: Market Size of Chronic Lower Back Pain in the US, USD Millions (2017-2028)
Figure 67: Market Size of Chronic Lower Back Pain by therapies in the United States, in USD Million (2017-2028)
Figure 68: Market Size of Chronic Lower Back Pain in Germany, USD Millions (2017-2028)
Figure 69: Market Size of Chronic Lower Back Pain by therapies in Germany, in USD Million (2017-2028)
Figure 70: Market Size of Chronic Lower Back Pain in France, USD Millions (2017-2028)
Figure 71: Market Size of Chronic Lower Back Pain by therapies in France, in USD Million (2017-2028)
Figure 72: Market Size of Chronic Lower Back Pain in Italy, USD Millions (2017-2028)
Figure 73: Market Size of Chronic Lower Back Pain by therapies in Italy in USD Million (2017-2028)
Figure 74: Market Size of Chronic Lower Back Pain in Spain, USD Millions (2017-2028)
Figure 75: Market Size of Chronic Lower Back Pain by therapies in Spain in USD Million (2017-2028)
Figure 76: Market Size of Chronic Lower Back Pain in the UK, USD Millions (2017-2028)
Figure 77: Market Size of Chronic Lower Back Pain by therapies in the UK in USD Million (2017-2028)
Figure 78: Market Size of Chronic Lower Back Pain in Japan, USD Millions (2017-2028)
Figure 79: Market Size of Chronic Lower Back Pain by therapies in Japan in USD Million (2017-2028)
Figure 80: Market Drivers
Figure 81: Market Barriers

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *